文献速递肝病消化道肿瘤与早癌

卡博替尼用于免疫检查点抑制剂治疗后肝细胞癌患者的多中心II期试验

Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
PubMed 文献 · J Hepatol · 2024-04-01

这项研究者发起的单臂II期多中心试验纳入47例既往接受过免疫检查点抑制剂(ICI)治疗且Child-Pugh A级的肝细胞癌(HCC)患者,每日口服卡博替尼60 mg。中位无进展生存期(PFS)为4.1个月(95%CI 3.3-5.3),中位总生存期(OS)为9.9个月(95%CI 7.3-14.4),1年OS率为45.3%;部分缓解3例(6.4%),疾病稳定36例(76.6%)。

要点

  • 卡博替尼在既往ICI治疗后HCC患者中显示疗效,中位PFS 4.1个月,中位OS 9.9个月。
  • 二线使用卡博替尼(n=27)中位PFS 4.3个月,中位OS 14.3个月。
  • 最常见3-4级治疗相关不良事件为血小板减少症(6.4%)。

核心结论

  • 卡博替尼在既往接受过ICI方案的HCC患者中显示出疗效;一线ICI方案后二线使用卡博替尼的生存数据为未来临床试验设计提供参考。
  • 既往治疗线数可作为随机研究的分层因素考虑。

研究设计与样本

  • 研究者发起的单臂II期临床试验,涉及香港和韩国的学术中心。
  • 纳入47例HCC患者,要求对既往ICI治疗无效且Child-Pugh A级肝功能,最多允许既往两线治疗。
  • 所有患者起始卡博替尼剂量为60 mg/天,主要终点为无进展生存期(PFS)。

主要发现

  • 47例患者于2020年10月至2022年5月入组;27例和20例分别接受过一线和二线既往治疗。
  • 中位随访11.2个月,中位PFS为4.1个月(95%CI 3.3-5.3)。
  • 中位OS为9.9个月(95%CI 7.3-14.4),1年OS率为45.3%。
  • 部分缓解3例(6.4%),疾病稳定36例(76.6%)。
  • 二线治疗(n=27)中位PFS 4.3个月(95%CI 3.3-6.7),中位OS 14.3个月(95%CI 8.9-NR);ICI方案有明确获益者(n=17)中位PFS 4.3个月(95%CI 3.3-11.0),中位OS 14.3个月(95%CI 9.0-NR)。

关键数值与推荐

  • 最常见3-4级治疗相关不良事件为血小板减少症(6.4%)。
  • 卡博替尼中位剂量为40 mg/天。
  • 既往治疗线数(一线 vs 二线)为独立预后因素(风险比=0.37;p=0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Prospective data on treatment after immune checkpoint inhibitor (ICI) therapy in hepatocellular carcinoma (HCC) are lacking. We conducted a phase II multicentre study on cabozantinib after ICI treatment in HCC. METHODS: This is an investigator-initiated, single-arm, clinical trial involving academic centres in Hong Kong and Korea. Key eligibility criteria included diagnosis of HCC, refractoriness to prior ICI-based treatment, and Child-Pugh A liver function. A maximum of two prior lines of therapy were allowed. All patients were commenced on cabozantinib at 60 mg/day. The primary endpoint was progression-free survival (PFS). RESULTS: Forty-seven patients were recruited from Oct 2020 to May 2022; 27 and 20 patients had received one and two prior therapies, respectively. Median follow-up was 11.2 months. The median PFS was 4.1 months (95% CI 3.3-5.3). The median overall survival (OS) was 9.9 months (95% CI 7.3-14.4), and the 1-year OS rate was 45.3%. Partial response and stable disease occurred in 3 (6.4%) and 36 (76.6%) patients, respectively. When used as a second-line treatment (n = 27), cabozantinib was associated with a median PFS and OS of 4.3 (95% CI 3.3-6.7) and 14.3 (95% CI 8.9-NR) months, respectively. The corresponding median PFS and OS were 4.3 (95% CI 3.3-11.0) and 14.3 (95% CI 9.0-NR) months, respectively, for those receiving ICI-based regimens with proven benefits (n = 17). The most common grade 3-4 treatment-related adverse event was thrombocytopenia (6.4%). The median dose of cabozantinib was 40 mg/day. The number of prior therapies was an independent prognosticator (one vs. two; hazard ratio = 0.37; p = 0.03). CONCLUSIONS: Cabozantinib demonstrated efficacy in patients who had received prior ICI regimens; survival data for second-line cabozantinib following first-line ICI regimens provide a reference for future clinical trial design. The number of prior lines of treatment may be considered a stratification factor in randomised studies. IMPACT AND IMPLICATIONS: Prospective data on systemic treatment following prior immune checkpoint inhibitor (ICI) therapy for hepatocellular carcinoma (HCC) are lacking. This phase II clinical trial provides efficacy and safety data on cabozantinib in patients who had received prior ICI-based treatment. Exploratory analyses showed that the performance of cabozantinib differed significantly when used as a second- or third-line treatment. The above data could be used as a reference for clinical practice and the design of future clinical trials on subsequent treatment lines following ICIs. GOV IDENTIFIER: NCT04588051.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Chan SL, Ryoo BY, Mo F, et al. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. J Hepatol. 2024. PMID: 38570034. doi:10.1016/j.jhep.2024.03.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。